Performance on the Latin American version of the Face-Name Associative Memory Exam (LAS-FNAME) distinguishes individuals with Mild Cognitive Impairment from age-matched controls in a sample from Argentina.
Saved in:
| Title: | Performance on the Latin American version of the Face-Name Associative Memory Exam (LAS-FNAME) distinguishes individuals with Mild Cognitive Impairment from age-matched controls in a sample from Argentina. |
|---|---|
| Authors: | Keller, G. (AUTHOR), Corvalan, N. (AUTHOR), Carello, M. A. (AUTHOR), Arruabarrena, M. M. (AUTHOR), Martínez-Canyazo, C. (AUTHOR), De Los Santos, L. (AUTHOR), Spehrs, J. (AUTHOR), Vila-Castelar, C. (AUTHOR), Allegri, R. F. (AUTHOR), Quiroz, Y. T. (AUTHOR), Crivelli, L. (AUTHOR) |
| Source: | Applied Neuropsychology: Adult. Nov/Dec2025, Vol. 32 Issue 6, p1777-1785. 9p. |
| Subjects: | Mild cognitive impairment, Alzheimer's disease, Psychometrics, Neuropsychological tests, Memory disorders, Latin Americans, Diagnostic examinations |
| Geographic Terms: | Argentina |
| Abstract (English): | Introduction: The Latin American Spanish version of the Face-Name Associative Memory Exam (LAS-FNAME) has shown promise in identifying cognitive changes in those at risk for Alzheimer's disease (AD). However, its applicability for Mild Cognitive Impairment (MCI) detection in the Latin American population remains unexplored. This study aims to analyze the psychometric properties in terms of validity and reliability and diagnostic performance of the LAS-FNAME for the detection of memory disorders in patients with amnestic MCI (aMCI). Materials and methods: The study included 31 participants with aMCI, diagnosed by a neurologist according to Petersen's criteria, and 19 healthy controls. Inclusion criteria for the aMCI group were to be 60 years of age or older, report cognitive complaints, have a memory test score (Craft Story 21) below a -1.5 z-score and have preserved functioning in activities of daily living. Participants completed LAS-FNAME and a comprehensive neuropsychological assessment. Results: LAS-FNAME showed the ability to discriminate against healthy controls from patients with aMCI (AUC= 75) in comparison with a gold-standard memory test (AUC = 69.1). LAS-FNAME also showed evidence of concurrent and divergent validity with a standard memory test (RAVLT) (r = 0.58, p <.001) and with an attention task (Digit Span) (r = −0.37, p =.06). Finally, the reliability index was very high (α = 0.88). Discussion: LAS-FNAME effectively distinguished aMCI patients from healthy controls, suggesting its potential for detecting early cognitive changes in Alzheimer's prodromal stages among Spanish speakers. [ABSTRACT FROM AUTHOR] |
| Abstract (Spanish): | La versión en español latinoamericano del Face-Name Memory Exam (LAS-FNAME) ha demostrado ser prometedora en la identificación de cambios cognitivos en personas con riesgo de padecer la enfermedad de Alzheimer (EA). Sin embargo, su aplicabilidad para la detección de Deterioro Cognitivo Leve (DCL) en la población latinoamericana permanece inexplorada. Este estudio tiene como objetivo analizar las propiedades psicométricas en términos de validez, confiabilidad y rendimiento diagnóstico del LAS-FNAME para la detección de trastornos de la memoria en pacientes con deterioro cognitivo leve amnésico (DCLa). El estudio incluyó a 31 participantes con DCLa, diagnosticado por un neurólogo según los criterios de Petersen, y 19 controles sanos. Los criterios de inclusión para el grupo de DCLa eran tener 60 años o más, presentar quejas cognitivas, tener una puntuación en la prueba de memoria (Craft Story 21) por debajo de una puntuación z de −1,5 y tener un funcionamiento preservado en las actividades de la vida diaria. Los participantes completaron el LAS-FNAME y una evaluación neuropsicológica exhaustiva. LAS-FNAME demostró adecuada capacidad para discriminar entre controles sanos y pacientes con DCLa (AUC = 75) en comparación con una prueba de memoria estándar (AUC = 69.1). Además, LAS-FNAME también mostró evidencia de validez concurrente y divergente con una prueba de memoria estándar (RAVLT) (r = 0.58, p < 0.001) y con una tarea de atención (Digit Span) (r = −0.37, p = 0.06). Finalmente, el índice de confiabilidad fue muy alto (α = 0.88). LAS-FNAME distinguió eficazmente a los pacientes con DCLa de los controles sanos, lo que sugiere su potencial para detectar cambios cognitivos tempranos en las fases prodrómicas del Alzheimer entre hispanohablantes. [ABSTRACT FROM AUTHOR] |
| Copyright of Applied Neuropsychology: Adult is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Psychology and Behavioral Sciences Collection |
|
Full text is not displayed to guests.
Login for full access.
|
|
| Abstract: | Introduction: The Latin American Spanish version of the Face-Name Associative Memory Exam (LAS-FNAME) has shown promise in identifying cognitive changes in those at risk for Alzheimer's disease (AD). However, its applicability for Mild Cognitive Impairment (MCI) detection in the Latin American population remains unexplored. This study aims to analyze the psychometric properties in terms of validity and reliability and diagnostic performance of the LAS-FNAME for the detection of memory disorders in patients with amnestic MCI (aMCI). Materials and methods: The study included 31 participants with aMCI, diagnosed by a neurologist according to Petersen's criteria, and 19 healthy controls. Inclusion criteria for the aMCI group were to be 60 years of age or older, report cognitive complaints, have a memory test score (Craft Story 21) below a -1.5 z-score and have preserved functioning in activities of daily living. Participants completed LAS-FNAME and a comprehensive neuropsychological assessment. Results: LAS-FNAME showed the ability to discriminate against healthy controls from patients with aMCI (AUC= 75) in comparison with a gold-standard memory test (AUC = 69.1). LAS-FNAME also showed evidence of concurrent and divergent validity with a standard memory test (RAVLT) (r = 0.58, p <.001) and with an attention task (Digit Span) (r = −0.37, p =.06). Finally, the reliability index was very high (α = 0.88). Discussion: LAS-FNAME effectively distinguished aMCI patients from healthy controls, suggesting its potential for detecting early cognitive changes in Alzheimer's prodromal stages among Spanish speakers. [ABSTRACT FROM AUTHOR] |
|---|---|
| ISSN: | 23279095 |
| DOI: | 10.1080/23279095.2024.2323627 |
